

October 22, 2019



## **CollPlant CEO Yehiel Tal Appointed to Serve on International Society for Biofabrication's Industry Relations Committee**

- The Industry Relations Committee represents all aspects of Biofabrication including roadmap, technologies, cell biology, large scale manufacturing, regulation, and commercialization**
- CollPlant delivered a poster presentation at International Conference on Biofabrication in Columbus, Ohio on October 21, 2019**

REHOVOT, Israel, Oct. 22, 2019 /PRNewswire/ -- **CollPlant** (NASDAQ: CLGN), a regenerative medicine company, today announced the Company's Chief Executive Officer Yehiel Tal was recently appointed as a member of the Industry Relations Committee of ISBF (International Society for Biofabrication). The committee convened during the International Conference on Biofabrication on October 20-22, 2019 in Columbus, Ohio.

Mr. Tal was appointed to the Industry Relations Committee in recognition of his deep involvement in the 3D bioprinting industry. The committee is tasked with advancing the Biofabrication industry by: serving as a mediator of academia-industry and industry-industry to promote and stimulate collaboration; developing mechanisms to facilitate translation of laboratory discoveries into manufactured products; and representing the industry in all Biofabrication aspects including roadmap, technologies, cell biology, large scale manufacturing, regulation, and commercialization.

At the International Conference on Biofabrication, CollPlant also presented a poster regarding CollPlant's rhCollagen technology titled, "Recombinant Human Type I Collagen a Flexible BioInk Platform for 3D Bioprinting."

"I am honored to be appointed to the International Society for Biofabrication's Industry Relations Committee, and to work with others who are shaping and advancing this promising field of regenerative medicine. In order to advance the development of ground breaking research and development into products, our committee will aim to create collaborative partnerships amongst stakeholders including industry, academia, and regulatory agencies. I am proud to be part of this process," stated Mr. Tal.

### **About the International Society for Biofabrication**

From basic science to medical applications, the biofabrication community convened at the

International Conference on Biofabrication (Biofabrication 2019). The field of biofabrication is dedicated to researching and integrating technologies such as bio-printing, bio-plotting, and bio-assembly into applications such as engineered tissue systems and regenerative medicine. The International Society for Biofabrication's (ISBF) core purpose is to foster scientific and technological innovation and excellence for the benefit of humanity. ISBF promotes the interaction between and convergence in the different disciplines of the field of Biofabrication, as well as between basic research and applied practice. Further, the Society aims to promote the cooperation with other scientific organizations and communities.

### **About CollPlant**

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

Our products address indications for the diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, we entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

For more information about CollPlant, visit <http://www.collplant.com>

### **Safe Harbor Statements**

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk, dermal fillers for aesthetics, VergenixSTR, and VergenixFG; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk, dermal fillers for aesthetics, VergenixSTR, and VergenixFG including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based

BiInk, dermal fillers for aesthetics, VergenixSTR, and VergenixFG; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**Contact at CollPlant:**

Eran Rotem

Deputy CEO & CFO

Tel: + 972-73-2325600

Email: [Eran@collplant.com](mailto:Eran@collplant.com)

📄 View original content: <http://www.prnewswire.com/news-releases/collplant-ceo-yehiel-tal-appointed-to-serve-on-international-society-for-biofabrications-industry-relations-committee-300942753.html>

SOURCE CollPlant